placebo + metformin

placebo + metformin refers to a combination regimen used as a comparator arm in clinical trials, specifically in studies evaluating new add-on therapies for type 2 diabetes mellitus (T2DM). In this context, patients continue their background therapy of metformin while receiving a placebo instead of the investigational agent. Metformin is a biguanide that lowers blood glucose levels by suppressing hepatic glucose production (gluconeogenesis), increasing peripheral glucose uptake, and improving insulin sensitivity. The placebo component is a pharmacologically inactive substance designed to match the appearance and administration of the experimental drug (such as the DPP-4 inhibitor retagliptin) to maintain the double-blind nature of the study. This combination serves as the control to assess the efficacy and safety of the experimental drug when added to standard-of-care metformin monotherapy.

Other names

placebo / metforminplacebo and metformin